AZD 6738

Drug Profile

AZD 6738

Alternative Names: AZD6738

Latest Information Update: 09 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Royal Marsden Hospital
  • Class Antineoplastics; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer
  • Phase I/II Non-small cell lung cancer; Solid tumours
  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia; Lymphoid leukaemia

Most Recent Events

  • 06 Jul 2017 Phase-II clinical trials in Gastric cancer (Combination therapy, Late-stage disease) in USA, France, South Korea and United Kingdom (PO) (AstraZeneca pipeline, July 2017)
  • 02 Jun 2017 Pharmacodynamic data from a phase Ib/II trial in Gastric cancer and Non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top